- Home
- PPCB vs ATHA Comparison
PPCB vs ATHA Comparison
Compare PPCB & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPCB
- ATHA
- Stock Information
- Founded
- PPCB 2007
- ATHA 2011
- Country
- PPCB Australia
- ATHA United States
- Employees
- PPCB N/A
- ATHA N/A
- Industry
- PPCB
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PPCB
- ATHA Health Care
- Exchange
- PPCB Nasdaq
- ATHA Nasdaq
- Market Cap
- PPCB 20.4M
- ATHA 18.2M
- IPO Year
- PPCB N/A
- ATHA 2020
- Fundamental
- Price
- PPCB $0.79
- ATHA $4.72
- Analyst Decision
- PPCB
- ATHA
- Analyst Count
- PPCB 0
- ATHA 0
- Target Price
- PPCB N/A
- ATHA N/A
- AVG Volume (30 Days)
- PPCB 225.5K
- ATHA 25.6K
- Earning Date
- PPCB 11-17-2025
- ATHA 11-06-2025
- Dividend Yield
- PPCB N/A
- ATHA N/A
- EPS Growth
- PPCB N/A
- ATHA N/A
- EPS
- PPCB N/A
- ATHA N/A
- Revenue
- PPCB N/A
- ATHA N/A
- Revenue This Year
- PPCB N/A
- ATHA N/A
- Revenue Next Year
- PPCB N/A
- ATHA N/A
- P/E Ratio
- PPCB N/A
- ATHA N/A
- Revenue Growth
- PPCB N/A
- ATHA N/A
- 52 Week Low
- PPCB $0.73
- ATHA $2.20
- 52 Week High
- PPCB $145.46
- ATHA $6.79
- Technical
- Relative Strength Index (RSI)
- PPCB N/A
- ATHA 61.31
- Support Level
- PPCB N/A
- ATHA $4.31
- Resistance Level
- PPCB N/A
- ATHA $4.95
- Average True Range (ATR)
- PPCB 0.00
- ATHA 0.37
- MACD
- PPCB 0.00
- ATHA -0.04
- Stochastic Oscillator
- PPCB 0.00
- ATHA 73.60
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.